Stockscreener 앱 받기
1.31
2.24%
-0.03
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Form 13D/A Allogene Therapeutics For: 1 October By Investing.com - Investing.com Nigeria
TPG Fully Divests Stake in Allogene Therapeutics, Reports Zero Ownership - Kalkine Media
At $1.55 a share, TPG funds sold Allogene Therapeutics (ALLO) stock. - Stock Titan
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Allogene CEO Zach Roberts Is Pushing to Make CAR T-Cell Therapy More Accessible: 'That's What Gets Me Out of Bed' - survivornet.com
Transcript : Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Allogene at Citi summit: mrD strategy and cash runway in focus - investing.com
Allogene: If MRD Holds, This Becomes A Completely Different Company - Seeking Alpha
Allogene Therapeutics Announces Retirement of Chief Financial Officer - The Globe and Mail
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026 - marketscreener.com
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026 - marketscreener.com
Allogene Therapeutics CFO Geoffrey Parker Announces Retirement Effective November 2026 - Kalkine Media
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com Nigeria
Allogene Therapeutics (ALLO) CFO Retirement Highlights Challenges Amid High Price-to-Sales Valuation - GuruFocus
Allogene Therapeutics CFO Geoffrey Parker to Retire - marketscreener.com
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com South Africa
Allogene CFO Geoffrey Parker to retire in November - Investing.com
Allogene's Geoffrey Parker to Retire as CFO, Effective Nov 6, 2026 - TradingView
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com UK
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - globenewswire.com
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - Yahoo Finance
Allogene Therapeutics CFO Geoffrey Parker to Retire - Yahoo Finance
Allogene Therapeutics Announces Participation in September Investor Conference - GlobeNewswire
Allogene Therapeutics Announces Participation in September Investor Conference - Yahoo Finance
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO) - Seeking Alpha
Allogene Therapeutics Inc. (ALLO) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allogene (NASDAQ: ALLO) exec share sale is tax ‘sell to cover’ - Stock Titan
Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares - Stock Titan
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Allogene (ALLO) Earnings Report: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Stock Move: Shares Finish 5.83% Down in the Available RecordEarnings Season Outlook - Vinanet
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth - Moomoo
Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History - Yahoo Finance
Allogene (ALLO) Q2 2026 Earnings Call Transcript - Yahoo Finance
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. (ALLO) Latest Stock News & Headlines - Yahoo Finance
ALLO Reiterated by Citizens -- Price Target Maintained at $6.00 - GuruFocus
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Nigeria
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com India
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Allogene Therapeutics (ALLO) Gains 3.54% as Shares Approach $2.15 ResistanceDemand Zone - vinanet.vn
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - Moomoo
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake wit - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - Yahoo Finance
4.22%
자본화:
|
볼륨(24시간):